NYSE:PBH

Prestige Consumer Healthcare (PBH) Stock Forecast, Price & News

$58.52

+0.60 (+1.04%)

(As of 03:51 PM ET)

Compare

Today's Range: $57.71
▼
$58.98
50-Day Range: $56.66
▼
$68.31
52-Week Range: $48.51
▼
$68.54

Volume: 82,096 shs
Average Volume: 246,801 shs
Market Capitalization: $2.90 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $82.00

Prestige Consumer Healthcare MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 39.6% Upside
$82.00 Price Target
Short Interest: Bearish
3.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: 1.17
Based on 3 Articles This Week
Insider Trading: Selling Shares
$2.30 M Sold Last Quarter
Proj. Earnings Growth: 6.73%
From $4.31 to $4.60 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

398th out of 963 stocks

Pharmaceutical Preparations Industry

174th out of 459 stocks

3.3

Analyst's Opinion

Consensus Rating
Prestige Consumer Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $82.00, Prestige Consumer Healthcare has a forecasted upside of 39.6% from its current price of $58.72.
Amount of Analyst Coverage
Prestige Consumer Healthcare has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.02% of the float of Prestige Consumer Healthcare has been sold short.
Short Interest Ratio / Days to Cover
Prestige Consumer Healthcare has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Prestige Consumer Healthcare has recently increased by 5.71%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Prestige Consumer Healthcare does not currently pay a dividend.
Dividend Growth
Prestige Consumer Healthcare does not have a long track record of dividend growth.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Prestige Consumer Healthcare has received a 42.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Dental floss", "Topical capsaicin", "Mouthwash", "Lice shampoo", "Montelukast", and "Yeast infection medicine" products. See details.
Environmental Sustainability
The Environmental Impact score for Prestige Consumer Healthcare is -2.35.

2.9

News and Social Media Coverage

News Sentiment
Prestige Consumer Healthcare has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Prestige Consumer Healthcare this week, compared to 2 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prestige Consumer Healthcare insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,300,353.00 in company stock.
Percentage Held by Insiders
Only 1.60% of the stock of Prestige Consumer Healthcare is held by insiders.
Percentage Held by Institutions
99.95% of the stock of Prestige Consumer Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Prestige Consumer Healthcare are expected to grow by 6.73% in the coming year, from $4.31 to $4.60 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prestige Consumer Healthcare is -34.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prestige Consumer Healthcare is -34.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Prestige Consumer Healthcare has a PEG Ratio of 1.68. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Prestige Consumer Healthcare has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Prestige Consumer Healthcare (NYSE:PBH) Stock

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

PBH Price History

30 days | 90 days | 365 days | Advanced Chart

PBH Stock News Headlines

September 22, 2023 | finance.yahoo.com

Why Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term

September 18, 2023 | markets.businessinsider.com

Canaccord Genuity Sticks to Its Buy Rating for Prestige Consumer Healthcare (PBH)

September 25, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

September 18, 2023 | americanbankingnews.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) SVP Sells $149,656.80 in Stock

September 16, 2023 | americanbankingnews.com

Prestige Consumer Healthcare (NYSE:PBH) vs. Acer Therapeutics (NASDAQ:ACER) Head-To-Head Review

September 11, 2023 | msn.com

Why Prestige Consumer Healthcare (PBH) is a Top Growth Stock for the Long-Term

September 6, 2023 | finance.yahoo.com

Down -11.27% in 4 Weeks, Here's Why You Should You Buy the Dip in Prestige Consumer Healthcare (PBH)

September 5, 2023 | finance.yahoo.com

Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference

September 25, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

September 5, 2023 | finance.yahoo.com

Prestige Consumer (PBH) Looks Well-Placed on Brand Strength

August 29, 2023 | msn.com

PBH vs. BSX: Which Stock Should Value Investors Buy Now?

August 16, 2023 | finance.yahoo.com

Looking for a Growth Stock? 3 Reasons Why Prestige Brands (PBH) is a Solid Choice

August 14, 2023 | seekingalpha.com

Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation

August 5, 2023 | seekingalpha.com

Prestige Consumer Healthcare Inc. 2024 Q1 - Results - Earnings Call Presentation

August 4, 2023 | uk.finance.yahoo.com

Prestige Brands Holdings, Inc. (PBH)

August 3, 2023 | finance.yahoo.com

Prestige Brands (PBH) Reports Q1 Earnings: What Key Metrics Have to Say

August 3, 2023 | finance.yahoo.com

Prestige Consumer Healthcare Inc. Reports First Quarter Fiscal 2024 Results

July 31, 2023 | finance.yahoo.com

Factors to Note Ahead of Prestige Consumer's (PBH) Q1 Earnings

July 11, 2023 | finance.yahoo.com

Prestige Consumer Healthcare to Release Fiscal 2024 First Quarter Earnings Results

July 6, 2023 | finance.yahoo.com

Prestige Consumer Healthcare Publishes Inaugural Sustainability Report

June 1, 2023 | finance.yahoo.com

Prestige Consumer Healthcare (NYSE:PBH) shareholders are still up 62% over 5 years despite pulling back 3.5% in the past week

May 31, 2023 | finance.yahoo.com

Goody’s® Introduces New “GET TO GOOD™” Marketing Campaign

May 23, 2023 | finance.yahoo.com

Dramamine® Eases Americans’ Travel Woes with ‘Ditch the Drama’ Sweepstakes Offering a Vacation to Anywhere in the World

May 9, 2023 | msn.com

DA Davidson Reiterates Prestige Consumer Healthcare (PBH) Neutral Recommendation

May 5, 2023 | finance.yahoo.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 4, 2023 | msn.com

Prestige Consumer (PBH) Q4 Earnings Top Estimates, Revenues Up

May 4, 2023 | finance.yahoo.com

Prestige Brands (PBH) Beats Q4 Earnings and Revenue Estimates

See More Headlines

Receive PBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

PBH Company Calendar

Last Earnings: 8/03/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Personal Products
Sector: Medical
Current Symbol: NYSE:PBH
CUSIP: 74112D10
CIK: 1295947
Web: www.prestigebrands.com
Phone: (914) 524-6800
Fax: 302-674-5266
Employees: 560
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $82.00
High Stock Price Forecast: $104.00
Low Stock Price Forecast: $71.00
Forecasted Upside/Downside: +41.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 13.44
P/E Growth: 1.68
Net Income: $-82,310,000.00
Net Margins: -7.46%
Pretax Margin: -8.50%
Return on Equity: 13.47%
Return on Assets: 5.95%

Debt

Debt-to-Equity Ratio: 0.89
Current Ratio: 2.66
Quick Ratio: 1.51

Sales & Book Value

Annual Sales: $1.13 billion
Price / Sales: 2.54
Cash Flow: $5.01 per share
Price / Cash Flow: 11.56
Book Value: $29.12 per share
Price / Book: 1.99

Miscellaneous

Outstanding Shares: 49,540,000
Free Float: 48,746,000
Market Cap: $2.87 billion
Optionable: Optionable
Beta: 0.59

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Ronald M. Lombardi (Age 59)
Chairman, Pres & CEO
Comp: $1.98M

Ms. Christine Sacco (Age 47)
Chief Financial Officer
Comp: $958.91k

Mr. Jeffrey Zerillo (Age 62)
Sr. VP of Operations
Comp: $496.91k

Mr. William C. P'Pool (Age 58)
Sr. VP, Gen. Counsel & Corp. Sec.
Comp: $769.98k

Mr. Adel Mekhail (Age 62)
Exec. VP of Marketing & Sales
Comp: $797.94k

Mr. Philip David Terpolilli
Director of Investor Relations

Dean Siegal
Director of Communications

Ms. Mary Beth Fritz
Sr. VP of Quality & Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PBH Stock - Frequently Asked Questions

Should I buy or sell Prestige Consumer Healthcare stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PBH shares.
View PBH analyst ratings or view top-rated stocks.
What is Prestige Consumer Healthcare's stock price forecast for 2023?: 3 brokerages have issued twelve-month price targets for Prestige Consumer Healthcare's stock. Their PBH share price forecasts range from $71.00 to $104.00. On average, they predict the company's share price to reach $82.00 in the next year. This suggests a possible upside of 41.6% from the stock's current price.
View analysts price targets for PBH or view top-rated stocks among Wall Street analysts.
How have PBH shares performed in 2023?: Prestige Consumer Healthcare's stock was trading at $62.60 at the start of the year. Since then, PBH stock has decreased by 7.5% and is now trading at $57.92.
View the best growth stocks for 2023 here.
When is Prestige Consumer Healthcare's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PBH earnings forecast.
How were Prestige Consumer Healthcare's earnings last quarter?: Prestige Consumer Healthcare Inc. (NYSE:PBH) posted its quarterly earnings data on Thursday, August, 3rd. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.01 by $0.05. The firm had revenue of $279.31 million for the quarter, compared to analysts' expectations of $278.79 million. Prestige Consumer Healthcare had a negative net margin of 7.46% and a positive trailing twelve-month return on equity of 13.47%. Prestige Consumer Healthcare's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 earnings per share.
What ETFs hold Prestige Consumer Healthcare's stock?: ETFs with the largest weight of Prestige Consumer Healthcare (NYSE:PBH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Schwab Ariel ESG ETF (SAEF), Global X Health & Wellness ETF (BFIT), SPDR S&P Pharmaceuticals ETF (XPH), ETC 6 Meridian Small Cap Equity ETF (SIXS), iShares U.S. Pharmaceuticals ETF (IHE) and Invesco S&P SmallCap Momentum ETF (XSMO).
What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?: Prestige Consumer Healthcare updated its FY 2024 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $4.27-$4.32 for the period, compared to the consensus estimate of $3.92. The company issued revenue guidance of $1.14 billion-$1.14 billion, compared to the consensus revenue estimate of $1.03 billion.
What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?: 8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Prestige Consumer Healthcare own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).
What is Prestige Consumer Healthcare's stock symbol?: Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."
Who are Prestige Consumer Healthcare's major shareholders?: Prestige Consumer Healthcare's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (18.20%), Dimensional Fund Advisors LP (7.37%), State Street Corp (3.78%), Westwood Holdings Group Inc. (2.56%), Geode Capital Management LLC (2.13%) and Ariel Investments LLC (1.87%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends.
How do I buy shares of Prestige Consumer Healthcare?: Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Prestige Consumer Healthcare's stock price today?: One share of PBH stock can currently be purchased for approximately $57.92.
How much money does Prestige Consumer Healthcare make?: Prestige Consumer Healthcare (NYSE:PBH) has a market capitalization of $2.87 billion and generates $1.13 billion in revenue each year. The company earns $-82,310,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.
How many employees does Prestige Consumer Healthcare have?: The company employs 560 workers across the globe.
How can I contact Prestige Consumer Healthcare?: Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The official website for the company is www.prestigebrands.com. The company can be reached via phone at (914) 524-6800, via email at irinquiries@prestigebrands.com, or via fax at 302-674-5266.

This page (NYSE:PBH) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial